Holen Sie sich die Stockscreener-App
7.87
5.78%
0.43
Handel nachbörslich:
7.94
0.07
+0.89%
Schlusskurs vom Vortag:
$7.44
Offen:
$7.4
24-Stunden-Volumen:
70,242
Relative Volume:
0.67
Marktkapitalisierung:
$50.78M
Einnahmen:
$5.75M
Nettoeinkommen (Verlust:
$-38.96M
KGV:
-0.6311
EPS:
-12.47
Netto-Cashflow:
$-32.63M
1W Leistung:
+7.51%
1M Leistung:
+34.53%
6M Leistung:
+1.42%
1J Leistung:
+31.39%
1-Tages-Spanne:
$7.40
$7.98
1-Wochen-Bereich:
$7.00
$7.98
52-Wochen-Spanne:
$2.92
$11.20
Kala Bio Inc Stock (KALA) Company Profile
Firmenname
Kala Bio Inc
Sektor
Branche
Telefon
781-996-5252
Adresse
1167 MASSACHUSETTS AVENUE, ARLINGTON, MA
Vergleichen Sie KALA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
KALA
Kala Bio Inc
|
7.87 | 48.01M | 5.75M | -38.96M | -32.63M | -12.47 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.92 | 99.42B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.55 | 58.99B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
432.52 | 56.35B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
646.60 | 39.02B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
307.51 | 34.25B | 3.81B | -644.79M | -669.77M | -6.24 |
Kala Bio Inc Stock (KALA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-11 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2022-03-30 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2021-08-06 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-09-14 | Herabstufung | Jefferies | Buy → Hold |
| 2020-07-23 | Eingeleitet | Northland Capital | Outperform |
| 2020-06-01 | Fortgesetzt | Oppenheimer | Outperform |
| 2020-05-27 | Bestätigt | H.C. Wainwright | Buy |
| 2020-03-09 | Hochstufung | BofA/Merrill | Neutral → Buy |
| 2019-12-17 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2019-03-14 | Eingeleitet | Jefferies | Buy |
Alle ansehen
Kala Bio Inc Aktie (KALA) Neueste Nachrichten
Wall Street Analysts Believe KALA BIO (KALA) Could Rally 74.73%: Here's is How to Trade - Yahoo Finance
What’s next for KALA BIO Inc. stock priceJuly 2025 Volume & Daily Entry Point Alerts - Newser
Technical analysis overview for KALA BIO Inc. stockMarket Performance Recap & Real-Time Volume Trigger Notifications - Newser
Comparing KALA BIO Inc. in custom built stock radars2025 Risk Factors & Intraday High Probability Alerts - Newser
Statistical indicators supporting KALA BIO Inc.’s strengthNew Guidance & Safe Entry Point Alerts - Newser
KALA BIO Inc. stock trend forecastPredictive AI Signals for Short-Term Trading - Newser
Can KALA BIO Inc. recover in the next quarterWeekly Profit Analysis & Fast Entry and Exit Trade Plans - Newser
Is KALA BIO Inc. a Top Dividend Stock to Watch in 2025High Probability Trade Outcome Prediction - Newser
Is KALA BIO Inc. showing insider buyingROIC-Focused Investment List - thegnnews.com
Why KALA BIO Inc. stock attracts strong analyst attentionMachine Learning Stock Movement Detector - Newser
How KALA BIO Inc. stock performs during market volatilityShort-Term Market Movement Forecast Report - Newser
Using portfolio simulators with KALA BIO Inc. includedFree Swing Setup With Technical Confirmation - Newser
What makes KALA BIO Inc. stock price move sharplyFree Risk Managed Intraday Trade Alerts - Newser
Can volume confirm reversal in KALA BIO Inc.Free AI Screening for Swing Trade Picks - Newser
Kala Bio Reports Q2 2025 Earnings: EPS -$1.82, Revenue Unavailable; Focus on Advancing KPI-012 for Rare Eye Diseases. - AInvest
Trend analysis for KALA BIO Inc. this weekWeekly Trend Watch with Market Signals - Newser
What drives KALA BIO Inc.’s stock priceStocks with 300% Upside - sisaissue.com
KALA BIO: Q2 Earnings Snapshot - Greenwich Time
KALA BIO (NASDAQ:KALA) Stock Rating Lowered by Wall Street Zen - Defense World
Momentum divergence signals in KALA BIO Inc. chartShort-Term Profit Alert With Entry Forecast - Newser
Kala Bio (KALA) Q2 Loss Widens 15% - AOL.com
KALA BIO Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Kala Bio Q2 Loss Widens 15%, KPI-012 Enrollment Completed - AInvest
Biotech's Long Game: Assessing KALA BIO's Q2 Loss in the Context of Strategic Innovation - AInvest
Kala Bio (KALA) Q2 Loss Widens 15% - The Motley Fool
KALA BIO, Inc. Completes Patient Enrollment in Phase 2b CHASE Trial for KPI-012 in Persistent Corneal Epithelial Defect, Reports Financial Results and Upcoming Milestones - Quiver Quantitative
KALA BIO, Inc. SEC 10-Q Report - TradingView
KALA BIO Reports Second Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewswire
KALA BIO Reports Second Quarter 2025 Financial Results and Provi - GuruFocus
Kala Bio shares rise 3.83% premarket after announcing presentation at H.C. Wainwright 5th Annual Ophthalmology Virtual Conference. - AInvest
KALA BIO to Present at H.C. Wainwright 5th Annual Ophthalmology Virtual Conference | KALA Stock News - GuruFocus
KALA BIO, Inc. to Present at H.C. Wainwright 5th Annual Ophthalmology Virtual Conference on August 13, 2025 - Quiver Quantitative
KALA BIO to present at H.C. Wainwright Ophthalmology Virtual Conference. - AInvest
KALA BIO to Present at H.C. Wainwright 5th Annual Ophthalmology Virtual Conference - GlobeNewswire
KALA BIO Showcases Breakthrough Eye Disease Treatments at Major Ophthalmology Conference - Stock Titan
Finanzdaten der Kala Bio Inc-Aktie (KALA)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.67%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):